Bristol Myers reported a better-than-expected 6% rise in fourth-quarter revenue, benefiting from strong sales growth in its cancer drugs.
from WSJ.com: US Business http://ift.tt/1hr4ffi
via IFTTT
from WSJ.com: US Business http://ift.tt/1hr4ffi
via IFTTT
No comments:
Post a Comment